Cyxone AB (publ) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the US patent application 17/891,462 entitled Rabeximod Compounds. The application covers the protection of salt forms of the compound Rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis. The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent.

When issued, the patent will be valid until 2042.